some of you may remember that around 3/4 weeks ago Devon PCT approved dasatinib and nilotinib for chronic and accelerated phases CML that were resistant to imatinib. See Newswire
I will try to find out what their plans are should NICE go ahead and give a negative FAD in January.
The commissioning group PHTCG obviously did not use the same model as NICE because they came to a different conclusion.
Sandy
The Peninsula Health Technology Commissioning Group (PHTCG) has come to a decision on the use of dasatinib and nilotinib in the management of chronic myeloid leukaemia.
Where clinically appropriate these drugs may be used for patients who are resistant to standard first line therapy with imatinib who are in either the chronic or accelerated phase of the disease.
They may also be used for patients in these phases who cannot tolerate imatinib.
Full text here:
www.devonpct.nhs.uk